Novigenix SA

NOVIGENIX is a Swiss precision medicine company founded in 2014 that focuses on leveraging ImmunoTranscriptomic technologies to revolutionize disease management, with a primary focus on cancer. Through their proprietary LITOseek platform, which incorporates advanced Machine Learning and artificial intelligence techniques, the company aims to use patient multi-omics data to map the immune system's response to disease onset and progression, ultimately providing personalized insights and solutions to optimize patient therapeutic journeys. This innovation is expected to lead to improved patient outcomes by identifying illnesses, optimizing therapies, and monitoring disease recurrence. Their product roadmap includes immuno-oncology patient stratification tools, early detection and recurrence monitoring for colorectal cancer, and therapy optimization systems for managing cancer patients. In their latest funding round, NOVIGENIX secured a notable $20.00M Series B investment on 15 November 2022. This investment is a testament to the confidence that investors have in the potential of the company's technologies and their ability to make a significant impact in the biotechnology industry. With its headquarters in Switzerland, NOVIGENIX is strategically positioned at the heart of a renowned hub for biotechnology innovation. Their cutting-edge approach and recent investment injection position them well for driving advancements in disease management and patient outcomes.